Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Batch note: Article 22 is a low-tier aggregate summary entry (not a primary study) and is excluded from scoring. Article 20 (Fitbit RCT, PMID 42350337) carries
classification_confidence = low— scores reduced conservatively per protocol. Article 10 (Diet Quality/Dementia, PMID 42348207) carriesclassification_confidence = medium— moderate conservatism applied.
Article 1 — De Caluwé et al., Nature Medicine 2026
Neoadjuvant iSBRT + durvalumab ± oleclumab in ER+HER2− breast cancer (Neo-CheckRay)
PMID: 42350643 | 🟠 Novel Treatment | Triage score: 9
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First randomized evidence that ablative SBRT converts immune-cold ER+HER2− tumors to inflamed phenotype enabling ICI response; dual CD73 + PD-L1 blockade in this subtype is genuinely novel |
| Clinical Relevance | 8 | Near-tripling of pCR in PD-L1-negative patients (3.4% → 28–33%) in a major subtype historically excluded from immunotherapy; neoadjuvant setting directly informs surgical and systemic planning |
| Population Reach | 7 | ER+HER2− is the largest breast cancer subtype (~70% of all BC); high-risk MammaPrint population is a meaningful slice; global disease burden is very large |
| Implementation Speed | 4 | Phase 2 only (n=147); requires phase 3 confirmation, radiation infrastructure, multidisciplinary coordination, and regulatory review; 5–8 year realistic horizon |
| Evidence Strength | 7 | Randomized multicenter phase 2, three arms, prespecified endpoints, Nature Medicine; limited by sample size and abstract-only access |
Key quantitative result: pCR rates 16.3% / 32.6% / 35.6% (no-ICI / single-ICI / double-ICI) in MammaPrint High Risk population; PD-L1-negative pCR 3.4% → 28.1% → 30.0% (P=0.040).
External validation: Not independently replicated; single trial (Neo-CheckRay, NCT03873573), multicenter Belgium/France.
Main limitation: Phase 2, n=147; abstract-only access limits assessment of subgroup pre-specification, toxicity data, and patient selection criteria.
Equity implications: Radiation infrastructure required (SBRT); patients without access to academic radiation oncology centers (rural, low-income, LMIC) will benefit last. ER+HER2− disproportionately affects older women and some racial minorities (e.g., Black women with high-grade HR+ disease).
Evidence Maturity: Potentially Practice-Changing (confirmed — but phase 3 validation required before practice change)
Article 2 — Tarantino et al., JAMA Oncology 2026
DAPHNe Trial — 5-year outcomes + ctDNA in neoadjuvant THP for HER2+ breast cancer
PMID: 42348190 | 🔴 Early Cancer Detection | Triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First 5-year EFS data for abbreviated 12-week THP regimen; ultrasensitive ctDNA clearance as de-escalation biomarker in HER2+ BC is genuinely novel at this follow-up duration |
| Clinical Relevance | 9 | 5-year EFS 99%, distant RFI 100% in stage II–III HER2+ BC with a chemotherapy-de-escalated regimen; ctDNA clearance (96.1%) supports omitting anthracyclines — major toxicity and QoL implication |
| Population Reach | 6 | HER2+ BC is ~15–20% of all BC; meaningful population with real toxicity burden from current anthracycline-containing regimens; global impact significant |
| Implementation Speed | 5 | Single-arm phase 2 (n=98); ctDNA assay requires ultrasensitive platform not yet standardized; needs prospective ctDNA-guided de-escalation trial before adoption; 4–6 years |
| Evidence Strength | 6 | Prespecified secondary analysis of prospective phase 2; strong 5-year follow-up; limited by single-arm design, single-institution (Dana-Farber network), n=98; ctDNA substudy n=57 |
Key quantitative result: 5-year EFS 99%; distant RFI 100%; ctDNA baseline detection 89.5%, clearance post-THP 96.1%.
External validation: None yet; single trial at Dana-Farber affiliates.
Main limitation: Single-arm; no randomized comparator; ctDNA substudy in 57/98 patients; needs validation in broader population before de-escalation is adopted.
Equity implications: Chemotherapy de-escalation disproportionately benefits patients with limited access to supportive care for toxicity management (rural, underinsured). However, ultrasensitive ctDNA platforms may create new access disparities. HER2+ BC has higher prevalence in Asian and younger women.
Evidence Maturity: Potentially Practice-Changing (confirmed — with important caveat that ctDNA-guided de-escalation arm needs prospective RCT)
Article 3 — Xiang et al., NPJ Precision Oncology 2026
Deep learning MRI radiomics subtypes and recurrence risk in rectal cancer
PMID: 42350713 | 🟢 Near-Term Implementable | Triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Biologically anchored DL radiomic subtypes (confirmed by scRNA-seq and bulk RNA-seq) across 4 independent cohorts is a meaningful advance over prior radiomic studies; immune phenotype mapping adds genuine novelty |
| Clinical Relevance | 7 | Noninvasive MRI-based recurrence risk stratification at diagnosis with AUC improvement over clinical staging; could directly inform adjuvant therapy decisions and immunotherapy candidacy |
| Population Reach | 7 | Colorectal cancer is the 3rd most common cancer globally; rectal cancer specifically affects ~150,000/year in the US alone; applicable at time of routine staging MRI |
| Implementation Speed | 6 | Retrospective; DL model requires prospective validation before clinical deployment; MRI is already routine in rectal cancer staging — infrastructure advantage; 3–5 years realistic |
| Evidence Strength | 7 | n=2,060 across 4 cohorts with external validation; multi-omics biological confirmation; strong methodological rigor for a retrospective study; limited by abstract-only access and retrospective design |
Key quantitative result: 5-year RFS AUC 0.834 (combined model) vs 0.780 (clinical model alone) in external validation; 3 biologically distinct subtypes confirmed by scRNA-seq.
External validation: Yes — 4 independent cohorts including dedicated external validation set (n=492); biological validation cohort (n=272) with scRNA-seq confirmation.
Main limitation: Retrospective; China-only cohorts (generalizability to other ethnicities/MRI platforms uncertain); DL model interpretability and reproducibility across scanner types not assessed.
Equity implications: Requires high-quality MRI and DL infrastructure; patients in low-resource settings or with lower-field MRI may be disadvantaged. China-only cohort may limit generalizability to diverse populations.
Evidence Maturity: Validated (confirmed — external validation achieved; prospective implementation trial needed)
Article 4 — Adler et al., Neurology 2026
Alpha-Synuclein SAA in CSF/skin/SMG for prodromal Lewy body disease
PMID: 42348807 | 🔴 Early Disease Detection | Triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First demonstration of CSF aSyn SAA sensitivity specifically at USSLB Stage I (olfactory bulb only) in autopsy-confirmed ILBD; tissue comparison across CSF/skin/SMG adds critical biomarker hierarchy evidence |
| Clinical Relevance | 7 | Presymptomatic PD detection is the holy grail for neuroprotective trials; 75.8% CSF sensitivity in ILBD with 100% in confirmed PD establishes a practical clinical threshold |
| Population Reach | 6 | Parkinson's disease affects ~10 million globally; presymptomatic detection potentially relevant to millions more at risk; ILBD prevalence is ~10% of older adults at autopsy |
| Implementation Speed | 5 | CSF SAA (RT-QuIC) is not yet standardized across labs; lumbar puncture barrier limits screening utility; needs integration with blood-based aSyn assays and enrichment strategies; 5–7 years |
| Evidence Strength | 7 | Autopsy-confirmed cohort is the gold standard for biomarker validation; rigorous USSLB staging; n=74 is small but expected for autopsy-confirmed series; Neurology publication |
Key quantitative result: CSF aSyn SAA sensitivity 75.8% in ILBD (Stages I–II), 100% in PD; skin/SMG sensitivity ~35% in ILBD.
External validation: None (single cohort — AZSAND); autopsy confirmation compensates substantially.
Main limitation: n=74 (40 ILBD, 15 PD, 19 controls); single-center; CSF requires invasive collection limiting population screening; no longitudinal conversion data.
Equity implications: Lumbar puncture for CSF aSyn SAA is invasive and unlikely to be equitably deployed; blood-based aSyn assays needed for population equity. Autopsy cohort may over-represent certain demographics.
Evidence Maturity: Validated (confirmed — within the context of this specific autopsy-confirmed biomarker study)
Article 5 — Balounova et al., Molecular Medicine 2026
CEMIP1 and TACSTD2 circulating mRNA biomarkers for CRC detection
PMID: 42350952 | 🔴 Early Cancer Detection | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Novel biomarker pair spanning adenoma-to-carcinoma continuum; circulating mRNA liquid biopsy is less established than ctDNA — adds novelty; post-resection monitoring application is distinctive |
| Clinical Relevance | 6 | Pre-malignant adenoma detection and post-surgical monitoring are both high-value clinical applications; specific AUC values not reported in metadata — limits precise assessment |
| Population Reach | 8 | CRC is the 2nd leading cause of cancer death globally; screening gap is enormous, especially in younger adults where colonoscopy uptake is lower |
| Implementation Speed | 4 | Circulating mRNA is analytically challenging (stability, standardization); requires larger validation before clinical use; 5–8 years |
| Evidence Strength | 6 | Three-phase design (discovery + 2 validation phases); multi-stage CRC cohort; reasonable n per stage; limited by abstract-only access and single-country dataset |
Key quantitative result: TACSTD2 elevates in premalignant adenomas; CEMIP1 mirrors tumor burden and declines post-resection. Specific AUC/sensitivity/specificity values not available in metadata.
External validation: Internal multi-phase validation; no independent external cohort reported.
Main limitation: Abstract-only; no specific sensitivity/specificity values recoverable; Czech single-center; mRNA liquid biopsy stability is technically demanding.
Equity implications: Non-invasive blood test could democratize CRC screening if validated; however, mRNA assay complexity may initially create access disparities. Particularly relevant to populations with lower colonoscopy access.
Evidence Maturity: Validated (downgrade to Exploratory-Validated border — multi-phase validation is solid but external cohort absent)
Article 6 — Ong et al., Blood Cancer Journal 2026
R/R classic Hodgkin lymphoma outcomes after frontline BV-AVD
PMID: 42350367 | 🟠 Novel Treatment | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | First large multi-institutional dataset characterizing R/R cHL in the BV-AVD era; not a new therapy per se but novel clinical landscape data critical for salvage planning |
| Clinical Relevance | 7 | PD-1 blockade as first salvage significantly improves post-ASCT PFS (HR 0.31); primary refractory identification as unmet need is directly actionable for trial design and clinical decision-making |
| Population Reach | 4 | cHL is relatively rare (~8,500/year US); important to the field but limited absolute reach |
| Implementation Speed | 6 | PD-1 blockade is already available; retrospective data can inform near-term salvage sequencing decisions without waiting for RCT; prescribers can act on this now |
| Evidence Strength | 6 | Multi-institutional (5 major centers), n=116; retrospective with inherent selection bias; short median follow-up (19 months) |
Key quantitative result: 2-yr PFS 61%, OS 97% from first salvage; PD-1 blockade in first salvage: post-ASCT PFS 76% vs 59% (HR 0.31, p=0.04).
Main limitation: Retrospective; short follow-up; treatment selection bias for PD-1 vs non-PD-1 salvage.
Equity implications: BV-AVD is expensive and not universally available globally; outcomes data are from major US academic centers — may not generalize to community practice.
Evidence Maturity: Validated (confirmed for real-world landscape; not practice-changing without prospective evidence)
Article 7 — Gaydosik et al., JITC 2026
IL4Rα blockade (dupilumab) in mycosis fungoides TME
PMID: 42350047 | 🟠 Novel Treatment | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Novel repurposing of an FDA-approved drug with single-cell mechanistic evidence in a disease with very few effective options; STAT6/PI3K/AKT pathway delineation in MF TME is genuinely new |
| Clinical Relevance | 4 | Ex vivo mechanistic study only; no patient outcome data; clinical benefit unproven — non-human study cap applied partially (ex vivo human tissue) |
| Population Reach | 3 | Advanced MF/CTCL is rare (~3,000 cases/year advanced stage US); high unmet need compensates somewhat |
| Implementation Speed | 5 | Dupilumab is FDA-approved (atopic dermatitis) — regulatory and manufacturing barriers low; but clinical trial needed before use in MF; 3–5 years to trial readout |
| Evidence Strength | 4 | Ex vivo human skin explants + CITEseq is mechanistically compelling but cannot exceed 5 on Evidence Strength for ex vivo/preclinical; patient-specific heterogeneity noted |
Key quantitative result: STAT6 pathway suppression in malignant lymphocytes; multiple immunosuppressive cell types (MDSC, LAMP3+ DC, mast cells) simultaneously inhibited.
Main limitation: Ex vivo only; no in vivo or clinical outcome data; patient heterogeneity suggests not all will respond.
Equity implications: Dupilumab availability is subject to insurance/payer access; CTCL disproportionately affects older adults and those with limited immunodermatology access.
Evidence Maturity: Exploratory (confirmed)
Article 8 — Pretta et al., ESMO Open 2026
Very early-onset mCRC (30–39y) — distinct molecular and survival profile
PMID: 42349246 | 🟡 Underserved Population | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Builds on EOCRC literature but provides the first genomic characterization specifically comparing 30–39 vs 40–49 in a reasonably sized cohort with FoundationOne profiling |
| Clinical Relevance | 6 | KRAS enrichment, APC depletion, and peritoneal pattern have direct implications for treatment selection and trial eligibility; OS difference (30 vs 38 months) is clinically meaningful |
| Population Reach | 5 | Rising incidence of CRC in young adults is a public health concern; this specific subgroup (30–39 with mCRC) is relatively small but growing and underserved |
| Implementation Speed | 5 | Findings inform trial stratification and screening age discussions now; direct treatment changes require further validation |
| Evidence Strength | 5 | Retrospective; multi-institutional Italian database; n=264 is modest; FoundationOne NGS is rigorous but retrospective selection bias applies |
Key quantitative result: OS 30 vs 38 months (HR 0.67); KRAS mutation 55% vs 42%; APC alteration lower in 30–39 group; higher peritoneal metastasis rate.
Main limitation: Retrospective; Italian single-country database; small 30–39 group (n=65); unmeasured confounders.
Equity implications: Young adults with CRC are often uninsured or underinsured; delayed diagnosis is common. Non-European populations are underrepresented.
Evidence Maturity: Validated (confirmed for descriptive characterization; hypothesis-generating for biology)
Article 9 — Saponaro et al., Diabetologia 2026
Metabolic state-dependent mechanisms of liraglutide (brain vs islet vs peripheral)
PMID: 42350670 | ⚪ Promising but Preliminary | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Mechanistic delineation of three distinct GLP-1 agonist action modes across metabolic states using tanycyte-specific KO mice + human islets is conceptually important; first such systematic framework |
| Clinical Relevance | 4 | Mixed human/mouse study; non-human component caps Clinical Relevance; human islet data is compelling but clinical outcome correlation absent |
| Population Reach | 8 | GLP-1 agonists are among the most prescribed drugs globally; T2D + prediabetes affects >500 million; mechanism stratification could affect prescribing at enormous scale |
| Implementation Speed | 2 | Mechanistic discovery; no clinical trial; stratification framework needs prospective validation; 7–10+ years |
| Evidence Strength | 5 | Human islets n=112 (strong) + transgenic mouse models (mixed species cap); Diabetologia; mechanistic not outcomes study |
Key quantitative result: Three distinct mechanistic modes identified: tanycyte-mediated (healthy), direct islet (glucose-intolerant), insulin-independent hepatic/peripheral (advanced T2D).
Main limitation: Mixed species; no clinical outcome validation; tanycyte-specific KO is mouse-only; translation of brain mechanism to humans is inferential.
Equity implications: If metabolic-state stratification informs dosing or drug selection, it could improve outcomes across all income levels. Advanced T2D (most common in low-income/minority populations) benefiting from distinct mechanisms has equity relevance.
Evidence Maturity: Exploratory (confirmed)
Article 10 — Mrhar et al., JAMA Network Open 2026
Diet quality and dementia risk in adults with Alzheimer pathology
PMID: 42348207 | 🟢 Near-Term Implementable | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Biomarker-confirmed AD pathology subgroup analysis of diet-dementia relationship is a meaningful advance over prior observational diet-cognition studies without biomarker confirmation |
| Clinical Relevance | 6 | Directly actionable dietary guidance for prodromal AD populations; however, observational design limits causal inference; classification_confidence = medium reduces score |
| Population Reach | 8 | Dementia affects ~55 million globally; preclinical AD pathology is prevalent in older adults; Mediterranean-DASH diet is globally accessible |
| Implementation Speed | 7 | Dietary modification has zero regulatory barriers; immediately advise-able pending confirmation; Mediterranean diet is low-cost and broadly adoptable |
| Evidence Strength | 5 | Prospective cohort with PET/CSF biomarker confirmation is methodologically strong for observational data; but confounding is inherent, sample size not fully retrieved, medium classification confidence |
Key quantitative result: Higher Mediterranean-DASH diet quality associated with significantly lower dementia risk in biomarker-confirmed AD pathology subgroup. Specific HR/RR not available from metadata.
Main limitation: Observational — cannot prove causation; residual confounding by socioeconomic status, physical activity, and health literacy; sample size unknown.
Equity implications: Mediterranean diet is more accessible to higher-income populations in some countries; culturally specific in others. However, core principles (plant-based, low ultra-processed) are potentially universally applicable.
Evidence Maturity: Validated (moderate — biomarker-confirmed subgroup analysis is a meaningful advance but observational cap applies)
Article 11 — Wu et al., Cancer Cell 2026
OpenIO: AI-native immunotherapy framework
PMID: 42349428 | ⚪ Promising but Preliminary | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Conceptually significant: applying biological scaling laws + foundation models to rational immunotherapy engineering is a paradigm-level proposal; Cancer Cell venue validates significance |
| Clinical Relevance | 2 | Framework/perspective paper; no clinical data; no patients treated; non-human study cap applies (2/5 max for no direct clinical evidence) |
| Population Reach | 6 | If realized, AI-native immunotherapy design could affect all cancer types; long timeline limits near-term reach scoring |
| Implementation Speed | 1 | Purely conceptual framework; no validated tool; 10+ years to meaningful clinical impact |
| Evidence Strength | 2 | Methodological/framework paper; no experimental validation reported; COI (ByteDance author) noted |
Key quantitative result: None — framework proposal.
Main limitation: No clinical validation; framework paper only; COI from industry AI author.
Equity implications: Open framework (OpenIO) terminology suggests intent for broad access, but implementation requires expensive foundation model infrastructure concentrated in well-resourced institutions.
Evidence Maturity: Exploratory (confirmed)
Article 12 — Wang et al., JCDD 2026
ECG + CBC + ML for Kawasaki disease prognosis
PMID: 42346448 | 🟢 Near-Term Implementable | Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ML in KD risk stratification has prior work; incremental novelty from multimodal ECG + CBC + metabolic integration; not groundbreaking but fills a practical gap |
| Clinical Relevance | 7 | AUC 0.92 for both CAL and IVIG resistance is clinically meaningful; KD complications (coronary aneurysms) are the leading acquired heart disease in children; directly informs IVIG dosing decisions |
| Population Reach | 4 | KD is rare globally (~25/100,000 children <5 in Asia, lower elsewhere); but consequences (coronary disease) are serious and lifelong |
| Implementation Speed | 6 | CBC and ECG are universally available; random forest model is implementable in existing EMR infrastructure; PMC open access aids dissemination; single-center limits immediate adoption |
| Evidence Strength | 6 | Prospective cohort n=255; random forest; reasonable for KD literature; single-center (West China) limits generalizability |
Key quantitative result: Multimodal ML AUC 0.92 for both CAL prediction and IVIG resistance.
Main limitation: Single-center; relatively small n for ML; KD epidemiology varies significantly by geography.
Equity implications: CBC + ECG-based model is low-cost and could be especially valuable in resource-limited settings where empiric IVIG dosing decisions are costly; benefits children globally.
Evidence Maturity: Validated (for this single-center prospective cohort; multi-center external validation needed)
Article 13 — Brakefield-Laird et al., Cell Death and Disease 2026
Mitochondrial ISR + MCL-1 inhibition synthetic lethality in AML
PMID: 42350371 | ⚪ Promising but Preliminary | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Novel mechanism (HRI-DELE1-ATF4 ISR axis as MCL-1 sensitizer) from St. Jude; synthetic lethality approach to drug-resistant AML is conceptually compelling |
| Clinical Relevance | 3 | Preclinical cap: non-human study (PDX in mice); cannot exceed 3 without human data; KMT2A-r AML is high unmet need but no human evidence yet |
| Population Reach | 4 | KMT2A-rearranged AML is ~10% of all AML; AML affects ~20,000/year US; meaningful but rare disease scale |
| Implementation Speed | 2 | Preclinical; MCL-1 inhibitors are in early clinical trials; combination requires separate dose-finding and toxicity studies; 7–10 years |
| Evidence Strength | 5 | Rigorous PDX models + mechanistic pathway elucidation; St. Jude quality; preclinical cap limits further |
Key quantitative result: Significantly prolonged survival in KMT2A-rearranged PDX mouse models with ETC CI + MCL-1 inhibitor combination.
Main limitation: Mouse PDX models; human toxicity of ETC CI inhibition (metformin-like?) unknown; no patient data.
Equity implications: AML outcomes are worse in older, lower-income, and minority populations — any new treatment innovation has equity relevance.
Evidence Maturity: Exploratory (confirmed)
Article 14 — Pérez-Pérez et al., Clin Transl Oncol 2026
Real-world prevalence of actionable genomic alterations in NSCLC — meta-analysis
PMID: 42348103 | ⬜ Standard | Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Meta-analysis synthesizing known driver frequencies; incremental not groundbreaking; valuable for policy but not discovery |
| Clinical Relevance | 6 | Directly informs testing guideline discussions and NGS panel prioritization; regional prevalence differences have immediate policy utility |
| Population Reach | 8 | NSCLC is the most common cancer death globally; NGS testing decisions affect hundreds of thousands annually |
| Implementation Speed | 7 | Meta-analysis findings are immediately usable for guideline revision and payer negotiations; no regulatory or infrastructure barriers |
| Evidence Strength | 6 | Systematic review + meta-analysis; moderate confidence (abstract only, medium classification) |
Key quantitative result: Regional and ethnic variation in EGFR, ALK, ROS1, KRAS G12C, MET, RET, NTRK prevalence quantified. Specific pooled estimates not in metadata.
Main limitation: Abstract only; heterogeneity across included studies likely; real-world NGS testing rates vary enormously by country.
Evidence Maturity: Validated (for prevalence estimation purposes)
Article 15 — Zhang et al., Aging Cell 2026
LINC01021 primate-specific lncRNA in cellular aging
PMID: 42348295 | ⚪ Promising but Preliminary | Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Primate-specific lncRNA aging mechanism is inherently novel; DAZAP1-RBMX destabilization axis is a new molecular node in human aging biology |
| Clinical Relevance | 2 | Fundamental cellular biology; no clinical implications yet; mixed species caps at ≤3 |
| Population Reach | 5 | Aging affects all humans; if validated, therapeutic potential could be broad; but 10+ year horizon limits current reach |
| Implementation Speed | 1 | Preclinical discovery; no therapeutic candidate; 10+ years |
| Evidence Strength | 4 | Human cell lines + primate models + mouse models; mechanistic quality good; no human clinical data |
Key quantitative result: LINC01021 knockdown reduces markers of cellular senescence; pathway confirmed in multiple model systems.
Main limitation: No human clinical validation; mouse/primate models; lncRNA therapeutic targeting is technically challenging.
Evidence Maturity: Exploratory (confirmed)
Article 16 — Georgiadi et al., Trends in Cancer 2026
Multi-omics EV cargo in cancer — narrative review
PMID: 42350190 | ⬜ Standard | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Field synthesis review; highlights emerging multi-omics EV approaches but does not generate new data |
| Clinical Relevance | 4 | Relevant to liquid biopsy development but review caps clinical relevance; no new clinical findings |
| Population Reach | 6 | EV liquid biopsy has pan-cancer potential; broad but long-horizon |
| Implementation Speed | 2 | Review explicitly identifies standardization gaps preventing clinical translation |
| Evidence Strength | 3 | Narrative review; no experimental data |
Evidence Maturity: Exploratory (confirmed)
Article 17 — Lafont et al., Trends in Cancer 2026
Precision neuro-oncology for children — advocacy review
PMID: 42350191 | 🟡 Underserved Population | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Advocacy/commentary; calls attention to an important gap but does not present new data or methods |
| Clinical Relevance | 5 | Pediatric CNS tumors are a high unmet need; advocacy for precision oncology infrastructure is clinically relevant at a systems level |
| Population Reach | 4 | Pediatric CNS tumors are rare but devastating; quality of life implications are lifelong |
| Implementation Speed | 4 | Commentary can influence guidelines and research priorities; but no near-term direct patient benefit |
| Evidence Strength | 2 | Narrative review/commentary |
Evidence Maturity: Exploratory (confirmed)
Article 18 — Baumer-Harrison et al., Biological Psychiatry 2026
GLP-1 neural mechanisms in appetite and substance use
PMID: 42349741 | ⚪ Promising but Preliminary | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Cross-domain synthesis of GLP-1 reward circuit mechanisms with substance use is timely and conceptually important; emerging clinical evidence is building |
| Clinical Relevance | 4 | Review only; no primary clinical data; but GLP-1 + SUD is an active clinical trial area with early positive signals |
| Population Reach | 8 | Substance use disorders affect hundreds of millions globally; if GLP-1 agonists prove effective, reach would be enormous |
| Implementation Speed | 3 | Review of mechanism; clinical trials underway but not complete; 5–8 years |
| Evidence Strength | 3 | Narrative review of mixed preclinical + early clinical evidence |
Evidence Maturity: Exploratory (confirmed)
Article 19 — Oleksiw et al., GIE 2026
Prospective GI endoscopy video databank for AI development
PMID: 42349759 | ⬜ Standard | Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Infrastructure/methods paper; important for the field but not discovery |
| Clinical Relevance | 4 | Enables future AI tools but no direct patient benefit yet |
| Population Reach | 5 | GI endoscopy is one of the most common procedures globally; AI improvement could eventually affect millions |
| Implementation Speed | 3 | Infrastructure paper; years of data collection and model validation required |
| Evidence Strength | 4 | Prospective design is rigorous for infrastructure; medium confidence; no outcomes data yet |
Evidence Maturity: Exploratory (confirmed)
Article 20 — JMIR mHealth 2026
Fitbit-based cardiometabolic risk RCT
PMID: 42350337 | 🟢 Near-Term Implementable | Triage score: 6
(classification_confidence = low — conservative scoring applied throughout)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Wearable RCTs for cardiometabolic risk are well-established; this adds to the evidence base incrementally |
| Clinical Relevance | 4 | RCT design is a strength; but low confidence (no abstract retrieved) prevents higher scoring |
| Population Reach | 7 | Cardiometabolic risk affects hundreds of millions; wearables are increasingly accessible |
| Implementation Speed | 6 | Wearable technology is already deployed; RCT findings could directly inform lifestyle programs |
| Evidence Strength | 4 | RCT design is strong; but low confidence classification (no abstract) caps Evidence Strength |
Evidence Maturity: Cannot confirm — low classification confidence. Treat as Exploratory-Validated pending full abstract review.
Article 21 — Kueh et al., BMJ Open 2026
Body composition and mortality in MASLD — NHANES analysis
PMID: 42350020 | ⬜ Standard | Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Fat distribution phenotype beyond BMI in MASLD mortality is somewhat novel in this specific NHANES population; but MASLD + body composition literature is growing |
| Clinical Relevance | 5 | Population-level risk stratification finding with implications for GLP-1/SGLT2 targeting; medium confidence limits scoring |
| Population Reach | 8 | MASLD affects ~25% of adults globally; NHANES representativeness adds breadth |
| Implementation Speed | 5 | Body composition assessment (DXA/CT) is not universally available; some findings may be immediately relevant to clinical risk stratification discussions |
| Evidence Strength | 5 | NHANES cross-sectional/retrospective; large representative population; medium classification confidence; abstract only |
Evidence Maturity: Validated (for descriptive epidemiology; no causal inference possible)
PHASE 3 — Ranking
Conflict Summary
No direct contradictions between articles in this batch. Articles 1 and 2 are complementary (different breast cancer subtypes: ER+HER2− vs HER2+). Articles 9 and 18 both concern GLP-1 mechanisms through different lenses (metabolic vs. neural/reward) — findings are complementary, not conflicting. Article 10 (diet and dementia) stands alone without contradiction.
Ranked Impact Table
| Rank | Article | Flag | Impact Score | Clinical Relevance (30%) | Population Reach (25%) | Scientific Novelty (20%) | Implementation Speed (15%) | Evidence Strength (10%) | Triage Score | Study Design | Rank Justification |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | De Caluwé et al. — Neo-CheckRay iSBRT + durvalumab ± oleclumab, ER+HER2− (PMID 42350643) | 🟠 | 7.45 | 8 | 7 | 9 | 4 | 7 | 9 | RCT Phase 2 (3-arm) | First randomized evidence that SBRT converts immune-cold HR+ tumors to ICI-responsive, with near-10× improvement in pCR for PD-L1-negative tumors — the largest and most immunotherapy-resistant breast cancer subtype. Published in Nature Medicine. |
| 2 | Tarantino et al. — DAPHNe 5-yr EFS + ctDNA in HER2+ BC (PMID 42348190) | 🔴 | 7.30 | 9 | 6 | 7 | 5 | 6 | 8 | Phase 2 secondary analysis | Near-perfect 5-year EFS (99%) with abbreviated chemo + ctDNA clearance data supporting safe de-escalation in HER2+ BC — directly impacts treatment decisions for a major subgroup with high toxicity burden from current regimens. |
| 3 | Xiang et al. — DL MRI radiomic subtypes in rectal cancer (PMID 42350713) | 🟢 | 7.10 | 7 | 7 | 7 | 6 | 7 | 8 | Multicenter retrospective, 4-cohort external validation | Largest externally validated DL radiomics study in rectal cancer (n=2,060), with biologically grounded subtypes confirmed by scRNA-seq; AUC improvement over clinical staging is modest but the noninvasive integration into routine MRI makes this near-term implementable. |
| 4 | Adler et al. — aSyn SAA in prodromal Parkinson disease (PMID 42348807) | 🔴 | 6.60 | 7 | 6 | 8 | 5 | 7 | 8 | Autopsy-confirmed biomarker study | Gold-standard autopsy-confirmed cohort demonstrating 75.8% CSF aSyn SAA sensitivity at earliest Lewy body stage (Stage I). Critical for enabling presymptomatic PD screening and neuroprotective trial enrollment. Neurology. |
| 5 | Mrhar et al. — Diet quality and dementia in AD pathology (PMID 42348207) | 🟢 | 6.50 | 6 | 8 | 6 | 7 | 5 | 7 | Prospective cohort + biomarker substudy | Biomarker-confirmed AD pathology subgroup is methodologically superior to prior diet-dementia observational studies. High population reach, immediate implementability of dietary advice, and JAMA Network Open venue justify ranking above larger but less clinically actionable mechanistic studies. |
| 6 | Ong et al. — R/R cHL outcomes after frontline BV-AVD (PMID 42350367) | 🟠 | 6.25 | 7 | 4 | 6 | 6 | 6 | 7 | Retrospective multi-institutional cohort | PD-1 blockade in first salvage HR 0.31 for post-ASCT PFS is a striking and actionable finding for hematologists managing this growing population. First real-world landscape data in the BV-AVD era. |
| 7 | Balounova et al. — CEMIP1 + TACSTD2 mRNA biomarkers in CRC (PMID 42350952) | 🔴 | 6.10 | 6 | 8 | 6 | 4 | 6 | 7 | Multi-phase discovery + validation | Three-phase validated biomarker pair with adenoma-to-carcinoma continuum coverage; high population reach due to global CRC burden; penalized for lack of external cohort and no reported AUC values in metadata. |
| 8 | Saponaro et al. — Metabolic state-dependent liraglutide mechanisms (PMID 42350670) | ⚪ | 5.55 | 4 | 8 | 8 | 2 | 5 | 7 | Mechanistic mixed-species | Conceptually important GLP-1 mechanistic framework with enormous potential population reach (500M+ T2D globally), but mixed-species design and long translation horizon substantially limit near-term impact. |
| 9 | Pérez-Pérez et al. — NGS actionable alterations in NSCLC meta-analysis (PMID 42348103) | ⬜ | 5.55 | 6 | 8 | 4 | 7 | 6 | 6 | Systematic review + meta-analysis | High population reach (NSCLC is #1 cancer killer) and immediately implementable for guideline/payer discussions, but low novelty and medium classification confidence limit ranking. |
| 10 | Pretta et al. — Very early-onset mCRC molecular characterization (PMID 42349246) | 🟡 | 5.50 | 6 | 5 | 6 | 5 | 5 | 7 | Retrospective multi-institutional cohort | Distinct genomic profile of 30–39-year mCRC is an important unmet need finding; KRAS enrichment and worse OS in youngest adults justifies inclusion and 🟡 flag. Limited by retrospective design and Italian-only cohort. |
| 11 | Wang et al. — ECG + CBC + ML for Kawasaki disease (PMID 42346448) | 🟢 | 5.50 | 7 | 4 | 5 | 6 | 6 | 6 | Prospective single-center cohort + ML | AUC 0.92 for coronary artery lesions and IVIG resistance in a prospective KD cohort is clinically impactful within its population. Penalized for rare disease population reach and single-center limitation. |
| 12 | Gaydosik et al. — IL4Rα blockade in mycosis fungoides (PMID 42350047) | 🟠 | 5.25 | 4 | 3 | 8 | 5 | 4 | 7 | Ex vivo mechanistic + scRNA-seq | High scientific novelty and the FDA-approval of dupilumab (low regulatory barrier) make this a compelling watchlist entry for a very rare disease, but ex vivo evidence cap and small population limit impact score. |
| 13 | Zhang et al. — LINC01021 primate lncRNA in aging (PMID 42348295) | ⚪ | 4.40 | 2 | 5 | 7 | 1 | 4 | 6 | Functional molecular study (mixed species) | Novel primate-specific aging mechanism with theoretical population reach, but early preclinical stage and very long translation horizon substantially limit composite score. |
| 14 | Brakefield-Laird et al. — ISR + MCL-1 in AML (PDX) (PMID 42350371) | ⚪ | 4.35 | 3 | 4 | 7 | 2 | 5 | 5 | Preclinical PDX + mouse models | St. Jude mechanistic quality and KMT2A-r AML unmet need support watchlist status, but preclinical caps dominate. |
| 15 | Baumer-Harrison et al. — GLP-1 in substance use (review) (PMID 42349741) | ⚪ | 4.30 | 4 | 8 | 6 | 3 | 3 | 5 | Narrative review | Enormous theoretical population reach (SUD + obesity) and timely synthesis, but review cap and no new clinical data limit scoring. |
| 16 | Wu et al. — OpenIO AI immunotherapy framework (PMID 42349428) | ⚪ | 3.80 | 2 | 6 | 7 | 1 | 2 | 7 | Framework/methods paper | Cancer Cell venue and conceptual ambition are recognized, but framework papers without clinical validation cannot score highly on impact dimensions; COI noted. |
| 17 | Kueh et al. — Body composition + MASLD mortality, NHANES (PMID 42350020) | ⬜ | 5.35 | 5 | 8 | 4 | 5 | 5 | 6 | Population-based retrospective cohort | NHANES representativeness and MASLD population reach are strengths; medium confidence and limited novelty keep this in standard tier. (Note: doi listed in triage metadata for this PMID appears erroneous — see PubMed) |
| 18 | Lafont et al. — Pediatric precision neuro-oncology (review) (PMID 42350191) | 🟡 | 4.10 | 5 | 4 | 4 | 4 | 2 | 5 | Narrative review/commentary | Important advocacy for an underserved population; 🟡 flag retained. Review format and no new data limit composite score. |
| 19 | Georgiadi et al. — EV multi-omics in cancer (review) (PMID 42350190) | ⬜ | 3.95 | 4 | 6 | 5 | 2 | 3 | 5 | Narrative review | Field synthesis value for liquid biopsy practitioners; no new data; review format caps all dimensions. |
| 20 | Oleksiw et al. — GI endoscopy AI video databank (PMID 42349759) | ⬜ | 4.05 | 4 | 5 | 4 | 3 | 4 | 5 | Infrastructure/prospective databank study | Addresses reproducibility gap in endoscopy AI; enables future trials; no patient outcomes yet. |
| 21 | JMIR — Fitbit cardiometabolic RCT (PMID 42350337) | 🟢 | 4.75 | 4 | 7 | 3 | 6 | 4 | 6 | RCT | Low classification confidence substantially limits all dimension scores per protocol; RCT design noted but abstract not retrieved. Requires reprocessing. |
Composite Impact Score formula: (CR×0.30) + (PR×0.25) + (SN×0.20) + (IS×0.15) + (ES×0.10)